Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer
TV offers a modest benefit over chemotherapy in r/mCC and reaches or surpasses the upper bounds of ICER applied in Spain when priced comparably to cemiplimab. The magnitude of clinical benefit remains uncertain.
Authors
- Antonio Olry de Labry Lima (ORCID: https://orcid.org/0000-0001-5448-1370)
- María Del Pilar Briceño-Casado (ORCID: https://orcid.org/0000-0002-4251-2843)
- Adrián Sánchez Vegas
- Emilio Jesús Alegre Del Rey (ORCID: https://orcid.org/0000-0003-0041-2024)
Institutions
- Instituto de Salud Carlos III (ES)
- Instituto de Investigación Biosanitaria de Granada (ES)
- Complejo Hospitalario Universitario de Granada (ES)
- Hospital Universitario Puerto Real (ES)
- Hospital Universitario de Valme (ES)
- Andalusian School of Public Health (ES)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1080/14737167.2025.2603941
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00